Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis

Oncologist - United States
doi 10.1634/theoncologist.2015-0397
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cross Sectional Analysis of Short Sale Determinants on U.S. Blue Chips

Financial Assets and Investing
2015English

Cross-Sectional Evolution of the U.S. City Size Distribution

Journal of Urban Economics
Urban StudiesEconomicsEconometrics
2001English

Large-Scale Computational Drug Repositioning to Find Treatments for Rare Diseases

npj Systems Biology and Applications
GeneticsMolecular BiologyBiochemistryApplied MathematicsSimulationComputer Science ApplicationsModelingDrug Discovery
2018English

Is the Current Approach to Reviewing New Drugs Condemning the Victims of Rare Diseases to Death? A Call for a National Orphan Drug Review Policy

CMAJ
Medicine
2006English

Repeat Participation in Annual Cross-Sectional Surveys of Drug Users and Its Implications for Analysis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2018English

The Sarbanes-Oxley Act: A Cost-Benefit Analysis Using the U.S. Banking Industry

Journal of Applied Business Research
International ManagementBusiness
2010English

Febuxostat Is a Novel Drug in Therapy for Gout

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy